

## Product Update

alogliptin 12.5mg plus metformin 1000mg combination tablet (Vipdomet<sup>®</sup>)  
SMC No. (998/14)

Takeda UK

05 September 2014

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

**alogliptin plus metformin combination tablet (Vipdomet<sup>®</sup>)** is accepted for restricted use within NHS Scotland.

**Indication under review:** in the treatment of adult patients aged 18 years and older with type 2 diabetes mellitus:

- as an adjunct to diet and exercise to improve glycaemic control in adult patients, inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of alogliptin and metformin.
- in combination with pioglitazone (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and pioglitazone.
- in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.

**SMC restriction:** to use in patients for whom this fixed dose combination of alogliptin and metformin is an appropriate choice of therapy and only when the addition of a sulphonylurea to metformin monotherapy is not appropriate.

For patients in whom dual combination therapy with metformin and alogliptin is appropriate it has the potential to reduce the pill burden at no additional cost.

Alogliptin/metformin is licensed for use in triple combination therapy with pioglitazone or as add-on to insulin. The manufacturer's submission related only to the use of alogliptin/ metformin in dual therapy, therefore SMC cannot recommend the use of alogliptin/ metformin in triple therapy with either pioglitazone or insulin.

**Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

This assessment is based on data submitted by the applicant company up to and including 06 August 2014.

**Chairman  
Scottish Medicines Consortium**